SolaranRx: Theranostics For Metastatic Melanoma
Executive Summary
SolaranRx Inc. is jumping on the theranostics bandwagon by tackling the deadly skin cancer melanoma, which for advanced cases has a staggering survival rate of only six months and a one-year mortality of 75%. The company’s lead compound, SRX-1177, is a novel peptide linked to a radioisotope that can preferentially attach to melanocortin-1, a unique receptor overexpressed on melanoma cells.